Corona and Hydroxychloroquine

Corona and Hydroxychloroquine

Hydroxychloroquine, marketed under the Traquenil trademark by Sanofi, is mainly indicated for the treatment of malaria, discoid and systemic lupus erythematosus and rheumatoid arthritis.

Antibiotic azithromycin (Zithromax) is studied in combination with Covid-19.

In the case of patients diagnosed with Covid-19, the US Food and Drug Administration (FDA) approved a combination of drugs for clinical examination. Patients in New York would take the first-in-line drug combination. Hydroxychloroquine developed by Sanofi is generically manufactured by a number of companies after the patent has expired.

Sanofi would have millions of doses in France for about 300,000 Covid-19 patients. Sanofi is also developing a novel coronavirus vaccine candidate using its recombinant DNA platform with the Biomedical Advanced Research and Development Authority (BARDA).

To support the global pandemic response of Covid-19, Novartis has committed up to 130 million 200 mg doses of generic hydroxychloroquine. Drugs for Covid-19 are also being developed in infected patients by other major drugs, including Teva and Mylan.

Identified as research drug

Hydroxychloroquine was identified by the World Health Organization as a research drug for Covid-19 efficacy. The suggested dosage of hydroxychloroquine for the clinical application is 200 mg in white tablets for oral administration.

Symptoms and Causes of Corona Virus

In Wuhan in the Hubei province of China in December 2019 Covid 19 is a severe acute respiratory syndrome (SARS) caused by the new coronavirus SARS-CoV-2. On 12 March 2020, the WHO announced the pandemic. This is a highly infectious disease that is transmitted by air droplets when a person is infected with coughing, sneezing or speaking and can also spread by touching an infected surface or subject.

How hydroxychloroquine works

For patients with Covid-19, hydroxychloroquine and its more toxic counterpart chloroquine have shown their effectiveness against SARS-CoV-2. In the in vitro studies, hydroxychloroquine with greater clinical protection profile and lower interaction with medicinal drugs than chloroquine have demonstrated anti-SARS-CoV activity.

Clinical studies for hydroxychloroquine

The French National Medicinal Safety Agency (ANSM), carried out by Didier Raoult and the team at the Mediterranean Infection University Hospital Institute in Marseille, France, has approved an open-label non-randomized clinical trial. There were 20 patients in total, while the control group was 16 patients.

On day 6 70 percent were not exhibiting signs of virology compared to 12.5 percent of the patients in the control group in the hydroxychloroquine-treated patients. In addition, six patients who have been diagnosed with hydroxychloroquine obtained azithromycin in routine electrocardiogram regulation for bacterial super-infection prevention. On Day Six, 100 percent (57.1 percent) of patients receiving Azithromycin hydroxychloroquine were virologically treated as opposed to 57.1 percent (12.5 percent) in the control group.

For Covid-19 patients, the viral loads of azithromycin-intensified SARS-CoV-2 were cleared efficiently for three to six days. Azithromycin acts both in vitro and extreme respiratory tract infections against Zika and Ebola viruses. The cure for Covid-19 was recommended to weaken the virus transmission chain and to curb disease spread around the world for patients with hydroxychloroquine and azithromycin.